Suppr超能文献

SGLT2 抑制剂的生酮作用对肾脏和心血管代谢的影响。

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors.

机构信息

AtheroThrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.

Instituto Ecuatoriano del Corazón (IECOR), Guayaquil 090513, Ecuador.

出版信息

Int J Mol Sci. 2023 Feb 18;24(4):4144. doi: 10.3390/ijms24044144.

Abstract

Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are glycosuric drugs that were originally developed for the treatment of type 2 diabetes mellitus (T2DM). There is a hypothesis that SGLT2i are drugs that are capable of increasing ketone bodies and free fatty acids. The idea is that they could serve as the necessary fuel, instead of glucose, for the purposes of cardiac muscle requirements and could explain antihypertensive effects, which are independent of renal function. The adult heart, under normal conditions, consumes around 60% to 90% of the cardiac energy that is derived from the oxidation of free fatty acids. In addition, a small proportion also comes from other available substrates. In order to meet energy demands with respect to achieving adequate cardiac function, the heart is known to possess metabolic flexibility. This allows it to switch between different available substrates in order to obtain the energy molecule adenosine triphosphate (ATP), thereby rendering it highly adaptive. It must be noted that oxidative phosphorylation in aerobic organisms is the main source of ATP, which is a result of reduced cofactors. These cofactors include nicotine adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2), which are the result of electron transfer and are used as the enzymatic cofactors that are involved in the respiratory chain. When there is an excessive increase in energy nutrients-such as glucose and fatty acids-which occur in the absence of a parallel increase in demand, a state of nutrient surplus (which is better known as an excess in supply) is created. The use of SGLT2i at the renal level has also been shown to generate beneficial metabolic alterations, which are obtained by reducing the glucotoxicity that is induced by glycosuria. Together with the reduction in perivisceral fat in various organs, such alterations also lead to the use of free fatty acids in the initial stages of the affected heart. Subsequently, this results in an increase in production with respect to ketoacids, which are a more available energy fuel at the cellular level. In addition, even though their mechanism is not fully understood, their vast benefits render them of incredible importance for the purposes of further research.

摘要

钠-葡萄糖共转运蛋白 2 抑制剂(SGLT2i)是一种原本用于治疗 2 型糖尿病(T2DM)的糖尿药物。有一个假说认为,SGLT2i 是能够增加酮体和游离脂肪酸的药物。其理念是,它们可以替代葡萄糖,成为心肌所需的必要燃料,并解释其独立于肾功能的降压作用。在正常情况下,成年心脏消耗的能量约有 60%至 90%来自游离脂肪酸的氧化。此外,还有一小部分来自其他可用的底物。为了满足心脏功能所需的能量需求,心脏具有代谢灵活性。这使它能够在不同的可用底物之间切换,以获得能量分子三磷酸腺苷(ATP),从而使其具有高度适应性。需要注意的是,需氧生物的氧化磷酸化是 ATP 的主要来源,这是还原辅因子的结果。这些辅因子包括烟酰胺腺嘌呤二核苷酸(NADH)和黄素腺嘌呤二核苷酸(FADH2),它们是电子转移的结果,用作参与呼吸链的酶辅因子。当能量营养素(如葡萄糖和脂肪酸)过度增加,而需求没有平行增加时,就会产生营养过剩(更常见的说法是供应过剩)的状态。在肾脏水平使用 SGLT2i 也已被证明可以产生有益的代谢改变,这些改变是通过减少由糖尿引起的糖毒性来实现的。与各器官内脏脂肪减少一起,这些改变还导致受影响心脏早期开始使用游离脂肪酸。随后,这会导致酮酸的产生增加,酮酸是细胞水平上更可用的能量燃料。此外,尽管其机制尚未完全理解,但它们的广泛益处使它们对进一步研究具有难以置信的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3200/9960541/e38054614887/ijms-24-04144-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验